Initial Experience With Hyperthermic Intraperitoneal Chemotherapy

Olivier Turrini, MD; Eric Lambaudie, MD; Marion Faucher, MD; Frédéric Viret, MD; Jean Louis Blache, MD; Gilles Houvenaeghel, MD; Jean Robert Delpero, MD

Background: Until 2004, we treated peritoneal carcinomatosis with cytoreductive surgery accompanied by perioperative systemic chemotherapy. From October 2004, we decided to initiate a hyperthermic intraperitoneal chemotherapy (HIPEC) program for this condition.

Objective: To determine the effect of HIPEC on postoperative outcomes at a single institution performing a high volume of cancer operations.

Method: Sixty consecutive patients underwent cytoreductive surgery plus HIPEC (oxaliplatin; 460 mg/m² in 2 L/m²) from October 1, 2004, through December 31, 2010. Usual perioperative factors were studied for 3 groups of patients who underwent HIPEC: 0 to 20 HIPEC procedures (period 1), 21 to 40 HIPEC procedures (period 2), and 41 to 60 HIPEC procedures (period 3).

Results: The mean peritoneal carcinomatosis index was 9.6, the mean duration of surgery was 410.7 minutes, and the mean blood loss was 450.2 mL/L. Mortality and morbidity were 0% and 33%, respectively. Grade III/IV morbidity (P=.02), transfusion (P<.01), and reintervention rate (P=.04) significantly decreased during the 3 periods. No difference was seen between the 3 periods with regard to mean peritoneal carcinomatosis index, operative duration, blood loss, mortality, overall morbidity, length of hospital stay, and readmission. The overall 1-, 3-, and 5-year survival rates of 26 patients with peritoneal carcinomatosis originating from colorectal cancer were 100%, 51%, and 37%, respectively. The overall median survival was 39 months.

Conclusions: We observed a significant reduction of grade III/IV morbidity, perioperative transfusion, and reintervention rate after 20 procedures. The introduction of the HIPEC program was successful because of the surgical team’s prior experience in cytoreductive and cancer operations.


PERITONEAL CARCINOMATOSIS (PC) originating from digestive or ovarian malignant tumors is ideally treated by cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Several studies1-11 have demonstrated that this is an effective and safe technique that has been used in numerous cancer centers. However, HIPEC is a complex procedure with directly related morbidity and mortality.12 Thus, many institutions are hesitant to initiate the HIPEC program because of the need of specific instrumentation,13 such as a heating circuit that requires a specific pump and close monitoring of intra-abdominal temperatures, and the likelihood of a poor postoperative course.

See Invited Critique at end of article

METHODS

Seventy-eight consecutive patients underwent exploratory laparotomy for PC at the Institut Paoli-Calmettes from October 1, 2004,
through December 31, 2010. According to the intraperitoneal findings, 60 patients (77%) underwent cytoreductive surgery followed by HIPEC. All patient data were prospectively entered into a clinical database approved by the institutional review board. All patients had asymptomatic PC, no extra-abdominal malignancy, an Eastern Cooperative Oncology Group performance status of 0 or 1, age younger than 70 years, no malnutrition (ie, <10% weight loss 3 months before surgery), and serum albumin level greater than 20.0 g/dL (to convert to grams per liter, multiply by 10).

**SURGERY AND HIPEC**

Surgery was performed through a median incision. Careful examination of the peritoneal cavity was possible after complete liberation of the digestive tract. The PC index (PCI) was used to classify the extension of PC. Resection of PCI was achieved according to the guidelines by Sugarbaker. completeness of cancer resection (CCR) by cytoreductive surgery was assessed by the surgeon at the end of the procedure and classified into 3 categories: CCR-0, no macroscopic residual cancer; CCR-1, no residual nodule greater than 5 mm in diameter; and CCR-2, every residual nodule greater than 5 mm in diameter. The consensus statement issued by the Peritoneal Surface Oncology Group International after the 2006 meeting in Milan concluded that the debate on the best method to deliver HIPEC is still open, and there is no sufficient evidence in the literature confirming the superiority of one technique or drug over the other in terms of outcome, morbidity, and safety to the personnel in the operating room. Thus, after cytoreduction surgery, at a mean temperature of 43°C for 30 minutes, an “open” HIPEC technique (the Coliseum technique) was performed intraperitoneally with administration of oxaliplatin (460 mg/m² in 2 L/m² of dextrose). Before the initiation of HIPEC, all patients were given a 1-hour infusion of intravenous fluorouracil (400 mg/m²) and leucovorin calcium (20 mg/m²) to potentiate oxaliplatin activity. In case of digestive resection, anastomosis was performed after evacuation of intraperitoneal chemotherapy. A nonaspirative drain was placed in the pelvic cavity.

**STUDY VARIABLES**

The evaluated variables included age, sex, primary tumor site, perioperative chemotherapy, PCI, digestive resection, associated resection (spleen, liver, and urinary tract), operative duration (in minutes), intraoperative blood loss (in milliliters), morbidity according to the Clavien-Dindo classification, mortality (30 days after surgery or before hospital discharge), length of hospital stay (in days), and readmission 30 days after hospital discharge. We separately evaluated the intraoperative criteria and postoperative course for the 3 groups of patients who underwent HIPEC: 0 to 20 HIPEC procedures (period 1), 21 to 40 HIPEC procedures (period 2), and 41 to 60 HIPEC procedures (period 3). The thoroughness or quality of resection for PC is difficult to analyze. As a surrogate marker, quality was assessed by evaluating the survival of patients who received HIPEC for PC originating from colorectal cancer.

**STATISTICAL ANALYSIS**

Data analysis was conducted with GraphPad Prism 5.0d (GraphPad Software, Inc) and Excel 2008 (Microsoft) software. Survival was measured from the time of HIPEC until death or the last known follow-up (censor date was October 1, 2011). Significant associations between categorical factors were assessed using the Fisher exact test. Categorical variables are described in terms of frequency and percentage. The distribution of continuous variables is described as mean (SD). The association of categorical factors with survival was assessed using the Kaplan-Meier method and was tested using the log-rank test. Statistical significance was set at _P_ < .05.

**RESULTS**

**PATIENT CHARACTERISTICS**

Patient characteristics are detailed in Table 1. No patients were lost to follow-up. Median(SD) follow-up was 41 (22) months (range, 10-83 months). The Eastern Cooperative Oncology Group performance status was 0 or 1 for all patients. Peritoneal carcinomatosis originated from colorectal cancer in 26 patients (43%), from ovarian cancer in 12 (20%), from appendix cancer in 10 (17%), from pseudomyxoma/mesothelioma in 10 (17%), from pancreatic cancer in 1 (2%), and from small-bowel cancer in 1 (2%). Fifty-three patients (88%) had previously been treated with systemic chemotherapy with a mean (SD) of 7.6 (4.9) cycles. Thirty-seven patients (62%) received systemic chemotherapy after HIPEC.

**SURGERY**

The mean (SD) PCI was 9.6 (4.2). Excision of PC was synchronous with resection of the primary tumor in 13 patients (22%). A CCR-0 resection was achieved in 55 patients (92%). The mean (SD) duration of surgery was 410.7 (145.4) minutes (range, 130-680 minutes). The mean (SD) blood loss was 450.2 (291.2) mL/L. Three patients (5%) had minor hepatectomy for synchronous liver metastasis.

**POSTOPERATIVE COURSES**

Postoperative courses are summarized in Table 2. Mortality and morbidity were 0% and 33%, respectively. He-

---

**Table 1. Characteristics of 60 Patients Who Underwent Cytoreduction Surgery Plus HIPEC**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>52.1 (11.6)</td>
</tr>
<tr>
<td>Sex, No.</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>20</td>
</tr>
<tr>
<td>Female</td>
<td>40</td>
</tr>
<tr>
<td>Primary tumor site, No. (%)</td>
<td></td>
</tr>
<tr>
<td>Colorectal</td>
<td>26 (43)</td>
</tr>
<tr>
<td>Ovary</td>
<td>12 (20)</td>
</tr>
<tr>
<td>Appendix</td>
<td>10 (17)</td>
</tr>
<tr>
<td>Pseudomyxoma/mesothelioma</td>
<td>10 (17)</td>
</tr>
<tr>
<td>Other</td>
<td>2 (3)</td>
</tr>
<tr>
<td>No. of cycles of chemotherapy before HIPEC</td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>1.5 (0.9)</td>
</tr>
<tr>
<td>No. (%)</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>7 (13)</td>
</tr>
<tr>
<td>1</td>
<td>22 (37)</td>
</tr>
<tr>
<td>2</td>
<td>23 (38)</td>
</tr>
<tr>
<td>≥3</td>
<td>8 (13)</td>
</tr>
<tr>
<td>No. of cycles of chemotherapy before HIPEC</td>
<td></td>
</tr>
<tr>
<td>HIPEC, mean (SD)</td>
<td>7.6 (4.9)</td>
</tr>
<tr>
<td>Adjuvant chemotherapy, No. (%)</td>
<td>37 (62)</td>
</tr>
</tbody>
</table>

Abbreviation: HIPEC, hyperthermic intraperitoneal chemotherapy.
matologic toxicities (13.3%) and digestive fistula (10%) represented the more common complications after HIPEC. Major complications (Clavien-Dindo grade III/IV complications) occurred in 10 patients (17%). A second operation was necessary in 11 patients (18%) because of digestive fistula (n=7), intra-abdominal hematoma (n=3), and bladder fistula (n=1). The mean (SD) length of hospital stay was 23 (13) days (range, 7-62 days). Readmission was needed for 3 patients (5%).

**LEARNING CURVE**

Table 3 shows the evolution of perioperative courses according to the 3 periods. Perioperative red cell transfusion (P<.01), grade III/IV morbidity (P=.02), and re-intervention rate (P=.04) significantly decreased during the 3 periods. No difference was observed between the 3 periods with regard to mean PCI, operative duration, blood loss, mortality, overall morbidity, length of hospital stay, and readmission.

**SURVIVAL**

The overall 1-, 3-, and 5-year survival rates of 26 patients with PC originating from colorectal cancer were 100%, 51%, and 37%, respectively; the corresponding disease-free survival rates were 42%, 25%, and 20%, respectively (Figure). The overall median survival was 39 months.

**COMMENT**

In this series, we examined the administration of the first 60 HIPEC procedures performed in a comprehensive cancer center. Our institution performs a high volume of oncologic operations: all surgeons who participated in the HIPEC program are experienced and skilled in oncologic surgery. Until 2005, patients with PC were treated...
with aggressive cytoreductive surgery and perioperative systemic chemotherapy. In 2003, Verwaal et al published a randomized trial showing the indisputable effect of HIPEC in selected patients (≤ 65 years old, with an Eastern Cooperative Oncology Group performance status of 0-1, asymptomatic PC, and completeness of cytoreductive surgery). Thus, when we started our HIPEC program in 2004, we opted for an open technique with intraperitoneal administration of oxaliplatin as described by Elias et al. Because of our experience with cytoreduction, the only learning curve that we experienced was with the introduction of HIPEC itself. Three major results have been obtained from our study.

**IMPORTANCE OF ABIDING BY THE ELIGIBILITY CRITERIA**

Our patients were subject to strict eligibility criteria that had been previously established: all patients had good clinical status, had no symptomatic disease, and were younger than 70 years. During the initiation of this new procedure, we strongly supported the criteria that had been previously established by an experienced surgical team. It was necessary to have favorable postoperative courses in the initial patients so that the medical and paramedical teams did not experience discouragement with biased, poor results. Conversely, we could not justify performing HIPEC in patients with limited PC: the mean PCI was 9.6, and our patients required multiple digestive and associated resection (hepatectomy and splenectomy), which confirmed that we achieved extended peritoneectomies usually associated with a high morbidity rate.

**PERIOPERATIVE OUTCOMES**

We reported zero mortality and acceptable morbidity rates (33%), which have been previously reported by other experienced centers. We also showed that accumulating cases of HIPEC did not affect the operative duration, mortality and morbidity rates, length of hospital stay (despite a tendency of decrease during the 3 periods), and readmission rate. We noted that digestive fistula and hematologic toxicities were the more common morbidities that have already been reported with the use of intraperitoneal oxaliplatin. Thus, the mean reintervention rate was 18%, but it decreased to 5% for the last 20 HIPEC procedures.

We did not observe a significant difference in intraoperative blood loss between the first and last 20 procedures. However, there was a trend in decreased bleeding (544 mL/L vs 403.5 mL/L; P = .06). Because patient characteristics (notably the PCI) and cytoreductive surgery did not differ between the 3 periods, it was necessary to examine other factors that could explain the decrease in bleeding and the reduction in perioperative transfusion, grade III/IV morbidity, and reintervention rates. During the first 20 procedures, we did not observe any specific delay between the last chemotherapy cycle and HIPEC and drug dilution (Elias et al recommended a dilution of 2 L/m²). It is likely that a delay of less than 1 month between the chemotherapy cycle and surgery could increase the hematologic toxicity of both systemic and intraperitoneal chemotherapy, leading to related complications. Two factors, delay of less than 1 month and administration of intraperitoneal oxaliplatin (and not mitomycin C), probably led to an accumulation of systemic oxaliplatin that is frequently used in digestive PC. Insufficient drug dilution similarly increased the concentration of intraperitoneal oxaliplatin with corresponding morbidity as reported by Elias et al. After correction of these 2 crucial points, the grade III/IV morbidity (P = .02) and perioperative red cell transfusion (P < .01) significantly decreased and the reintervention rate (P = .04) decreased from 35% to 5%.

**ONCOLOGIC RESULTS**

The quality of resection was excellent with a CCR-0 resection rate of 91.7%. This result was not surprising with our extensive experience with cytoreduction in patients with PC. This highlighted our capacity to evaluate the resectability of PC. For HIPEC treatment administered to patients whose PC originated from colorectal cancer, we observed a median survival of 39 months and a 5-year overall survival of 39%, similar to a recently reported large series. The median disease-free survival (11 months) was similarly consistent with the literature.

If eligibility criteria and pharmaceutical drug recommendations are strictly observed, we supposed that center volume and surgeons with sufficient experience treating cancer and with previous experience with PC resection would improve the patient’s postoperative courses. In 2007, Smeenk et al published their series of PC treatment with HIPEC and affirmed that a minimum of 130 procedures was required to reach acceptable postoperative outcomes. Paradoxically, our findings are reinforced by this publication. Smeenk et al initially accumulated their surgical experience while performing both cytoreductive surgery and HIPEC in 1996. In that era, proper peritoneectomy technique, patient selection, phar-
macology of HIPEC, and perioperative care were not well established. Thus, a long learning curve was needed to control each part of the procedure and consequently improve perioperative courses.

In conclusion, our initial program with HIPEC was safe (no perioperative deaths occurred) and provided survival benefits comparable with HIPEC performed in an experienced center. We observed a significant reduction in grade III/IV morbidity and reinsertion rate after 20 procedures. Our encouraging results have to be moderated by the previous experience of our team in aggressive cytoreductive surgery, the high volume of cancer operations performed in our center, and the cancer treatment experience of the surgeons who initiated and developed the HIPEC program.

Accepted for Publication: March 28, 2012.
Published Online: June 18, 2012. doi:10.1001/archsurg.2012.988
Correspondence: Olivier Turrini, MD, Department of Surgical Oncology, Institut Paoli-Calmettes, 232 Bd de Sainte Marguerite, 13009 Marseille, France (turrinio@tpc.unicancer.fr).

Author Contributions: Drs Turrini, Viret, and Delpero take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Turrini, Lambaudie, Viret, and Houvenaeghel. Acquisition of data: Turrini, Lambaudie, Faucher, Viret, Blache, and Houvenaeghel. Analysis and interpretation of data: Turrini, Viret, Blache, and Delpero. Drafting of the manuscript: Turrini and Viret. Critical revision of the manuscript for important intellectual content: Turrini, Lambaudie, Faucher, Viret, Blache, Houvenaeghel, and Delpero. Statistical analysis: Turrini. Administrative, technical, and material support: Blache. Study supervision: Turrini, Lambaudie, Faucher, Viret, Houvenaeghel, and Delpero. Financial Disclosure: None reported.

REFERENCES